• Co-founded two highly successful life science companies: RTI Surgical, Inc. and AxoGen, Inc., both now publicly traded (NASDAQ: RTIX, AXGN)
• Former CEO of Florida Institute for Commercialization of Public Research
• Visionary and innovator in medical technology, regenerative medicine
• Successfully launched, managed, or advised numerous biotech startup companies

• Accomplished pharmaceutical executive with >25 years of demonstrated success developing brand name and generic drug products, Dr. Bittorf has taken more than 30 products to market.
• Leadership positions with Curis Inc., Flatley Discovery Lab, Trek Therapeutics, Compaction Simulation Forum, Living Proof Inc., and Vertex Pharmaceuticals.
• Deep expertise with GMP, risk management, business development, regulatory process, and formulation and manufacturing techniques from feasibility through commercialization stages.
• Excels at driving innovation resulting in cost savings and improved product control, engaging stakeholders to secure funding for technology investments, and leading regulatory submissions of Quality by Design initiatives.

• World-renowned addiction expert with 45+ years of experience studying effects of opioids and other drugs
• Authored over 1000 articles, chapters and abstracts in scientific journals
• Former Consultant to White House Office of Drug Policy
• Emeritus Eminent Scholar, Distinguished Professor and former Chair of Psychiatry at the University of Florida
• Director of Research, Drug Enforcement Agency (DEA) Educational Foundation

• Addiction expert and prominent advocate for treatment of drug addiction, criminal justice reform, and developing resources to help families in crisis
• President and CEO of the Addiction Policy Forum
• Appointee to Presidential Drug-Free Communities Commission
• Contributed to national drug-related legislative policy, including the Second Chance Act, the Drug Impaired Driving Act, the Drug-Free Workplace Act, and the Drug Free Communities Act

• Managing director and co-head of the M&A Buyside Advisory at Fifth Third Securities
• Managing director at Praxis Partners LLC
• Expert in corporate valuation, M&A, venture finance, entrepreneurship, corporate strategy, cross-border acquisitions
• CPA with 30+ years of operational, strategic and transactional M&A advisory experience

• Over two decades Product Development experience in Medical Device, HCT/Ps, Biologic, and Pharmaceutical industries
• Directed R&D at AuxThera Inc., AxoGen Inc. (NASDAQ: AXGN), RTI Surgical, Inc. (NASDAQ: RTIX) and other biotechnology companies
• Brings practical expertise especially for startup and small to mid-size companies